116 related articles for article (PubMed ID: 12026536)
1. [Evaluation of effectiveness and safety of three year immunotherapy with mixed grass pollen allergens].
Gietkiewicz K; Fal AM; Małolepszy J
Pol Arch Med Wewn; 2001 Dec; 106(6):1163-8. PubMed ID: 12026536
[TBL] [Abstract][Full Text] [Related]
2. [The influence of a three-year preseasonal specific immunotherapy on selected parameters of allergic inflammation in pollinosis patients].
Fal AM; Gietkiewicz K; Obojski A; Medrala W; Małolepszy J
Pneumonol Alergol Pol; 2002; 70(1-2):78-86. PubMed ID: 12148181
[TBL] [Abstract][Full Text] [Related]
3. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
4. Oral allergy syndrome in patients with airborne pollen allergy treated with specific immunotherapy.
Czarnecka-Operacz M; Jenerowicz D; Silny W
Acta Dermatovenerol Croat; 2008; 16(1):19-24. PubMed ID: 18358104
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
6. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid.
Corrigan CJ; Kettner J; Doemer C; Cromwell O; Narkus A;
Allergy; 2005 Jun; 60(6):801-7. PubMed ID: 15876311
[TBL] [Abstract][Full Text] [Related]
8. Hyposensitization therapy of Parietaria-sensitive patients with a tyrosine adsorbed allergoid, Pollinex Parietaria (Bencard Parietaria).
Bonifazi F; Antonicelli L; Bilò MB; Pucci S; Taylor IH; Wheeler AW; Youlten LJ
J Investig Allergol Clin Immunol; 1991 Feb; 1(1):37-44. PubMed ID: 1669563
[TBL] [Abstract][Full Text] [Related]
9. Pollinex Parietaria (Bencard Parietaria), a new allergoid for treatment of patients sensitive to Parietaria pollen.
Resta O; Carnimeo N; Foschino MP; Taylor I; Wheeler AW; Youlten LJ
J Investig Allergol Clin Immunol; 1991 Apr; 1(2):129-37. PubMed ID: 1669569
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens.
Quercia O; Bruno ME; Compalati E; Falagiani P; Mistrello G; Stefanini GF
Eur Ann Allergy Clin Immunol; 2011 Dec; 43(6):176-83. PubMed ID: 22360134
[TBL] [Abstract][Full Text] [Related]
11. Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy.
Panzner P; Petráš M; Sýkora T; Lesná IK; Liška M
Allergy Asthma Proc; 2011; 32(2):142-50. PubMed ID: 21439167
[TBL] [Abstract][Full Text] [Related]
12. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro).
McCormack PL; Wagstaff AJ
Drugs; 2006; 66(7):931-8. PubMed ID: 16740007
[TBL] [Abstract][Full Text] [Related]
13. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
Roberts G; Hurley C; Turcanu V; Lack G
J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
[TBL] [Abstract][Full Text] [Related]
14. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland.
Brüggenjürgen B; Reinhold T
J Med Econ; 2018 Apr; 21(4):374-381. PubMed ID: 29271271
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment.
González P; Florido F; Sáenz de San Pedro B; de la Torre F; Rico P; Martín S
J Investig Allergol Clin Immunol; 2002; 12(4):263-71. PubMed ID: 12926186
[TBL] [Abstract][Full Text] [Related]
17. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
Hordijk GJ; Antvelink JB; Luwema RA
Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of sublingual coseasonal immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy--preliminary data.
Ariano R; Panzani RC; Mistrello G
Eur Ann Allergy Clin Immunol; 2005 Mar; 37(3):103-8. PubMed ID: 15918297
[TBL] [Abstract][Full Text] [Related]
19. Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients.
Pfaar O; Biedermann T; Klimek L; Sager A; Robinson DS
Allergy; 2013 Oct; 68(10):1306-13. PubMed ID: 23991896
[TBL] [Abstract][Full Text] [Related]
20. Short-term preseasonal immunotherapy: is early clinical efficacy related to the basophil response?
Kepil Özdemir S; Sin BA; Güloğlu D; İkincioğulları A; Gençtürk Z; Mısırlıgil Z
Int Arch Allergy Immunol; 2014; 164(3):237-45. PubMed ID: 25170594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
